View Item 

Show simple item record

IMP Dehydrogenase Inhibitors as Immunomodulators

dc.contributor.authorMitchell, Beverly S.en_US
dc.contributor.authorDayton, Jennifer S.en_US
dc.contributor.authorTurka, Laurence A.en_US
dc.contributor.authorThompson, Craig B.en_US
dc.date.accessioned2010-06-01T21:50:32Z
dc.date.available2010-06-01T21:50:32Z
dc.date.issued1993-06en_US
dc.identifier.citationMITCHELL, BEVERLY S.; DAYTON, JENNIFER S.; TURKA, LAURENCE A.; THOMPSON, CRAIG B. (1993). "IMP Dehydrogenase Inhibitors as Immunomodulators." Annals of the New York Academy of Sciences 685(1 Immunomodulating Drugs ): 217-224. <http://hdl.handle.net/2027.42/74880>en_US
dc.identifier.issn0077-8923en_US
dc.identifier.issn1749-6632en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74880
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8103312&dopt=citationen_US
dc.format.extent422750 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1993 The New York Academy of Sciencesen_US
dc.titleIMP Dehydrogenase Inhibitors as Immunomodulatorsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelScience (General)en_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumHoward Hughes Medical Institute University of Michigan Ann Arbor, Michigan 48109en_US
dc.contributor.affiliationotherDepartments of Pharmacologyen_US
dc.contributor.affiliationotherInternal Medicineen_US
dc.contributor.affiliationotherUniversity of North Carolina Chapel Hill, North Carolina 27599 Departments of Internal Medicineen_US
dc.contributor.affiliationotherMicrobiology/Immunologyen_US
dc.identifier.pmid8103312en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74880/1/j.1749-6632.1993.tb35869.x.pdf
dc.identifier.doi10.1111/j.1749-6632.1993.tb35869.xen_US
dc.identifier.sourceAnnals of the New York Academy of Sciencesen_US
dc.identifier.citedreferenceJackson, R. C. & G. Weber. 1975. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256: 331 – 333.en_US
dc.identifier.citedreferenceKoyama, H. & M. Tsuji. 1983. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem. Pharmacol. 32: 3547 – 3553.en_US
dc.identifier.citedreferenceSakaguchi, K., M. Tsujino, M. Hayashi, K. Kawai, J. Mizuno & K. Hayand. 1976. Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells. J. Antibiotics (Tokyo) 29: 1320 – 1327.en_US
dc.identifier.citedreferenceIchikawa, Y., H. Ihara, S. Takahara, K. Takada, G. R. Shrestha, M. Ishibashi, M. Arima, S. Sagawa & T. Sonoda. 1984. The immunosuppressive mode of action of mizoribine. Transplantation 38: 262 – 267.en_US
dc.identifier.citedreferenceKusaba, R., O. Otubo, H. Sugimoto, I. Takahashi, Y. Yamada, J. Yamauchi, N. Akiyama & T. Inou. 1981. Immunosuppressive effect of bredinin in the management of patients with renal transplantation. In Proceedings of the European Dialysis Transplantation Association 18: 420 – 425.en_US
dc.identifier.citedreferenceAmemiya, H., S. Suzuki, H. Watanabe, R. Hayashi & S. Niiya. 1989. Synergistically enhanced immunosuppressive effect by combined use of cyclosporine and mizoribine. Transplant. Proc. 21: 956 – 958.en_US
dc.identifier.citedreferenceAmemiya, H., S. Suzuki, S. Niiya, H. Watanabe & T. Kotake. 1988. Synergistic effect of cyclosporine and mizoribine on survival of dog renal allografts. Transplantation 46: 768 – 771.en_US
dc.identifier.citedreferenceAso, K., H. Uchida, K. Sato, K. Yokota, T. Osakabe, Y. Nakayama, M. Ohkubo, K. Kumano, T. Endo, K. Koshiba, K. Watanabe & N. Kashiwagi. 1987. Immuno-suppression with low-dose cyclosporine combined with bredinin and prednisolone. Translant. Proc. 19: 1955 – 1958.en_US
dc.identifier.citedreferenceTurka, L. A., J. Dayton, G. Sinclair, C. B. Thompson & B. S. Mitchell. 1991. Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug mizoribine. J. Clin. Invest. 87: 940 – 948.en_US
dc.identifier.citedreferenceSidi, Y. & B. S. Mitchell. 1984. 2'-Deoxyguanosine toxicity of B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. J. Clin. Invest. 74: 1640 – 1648.en_US
dc.identifier.citedreferenceDayton, J. S., L. A. Turka, C. B. Thompson & B. S. Mitchell. 1992. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide pools. Mol. Pharmacol. 41: 671 – 676.en_US
dc.identifier.citedreferenceCohen, M. B., J. Maybaum & W. Sadee. 1981. Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells. J. Biol. Chem. 256: 8713 – 8717.en_US
dc.identifier.citedreferenceElion, G. B. & G. H. Hitchings. 1975. Azathioprine. Handb. Exp. Pharmacol. 38: 404 – 425.en_US
dc.identifier.citedreferenceWolberg, G. 1988. Antipurines and purine metabolism. Handb. Exp. Pharmacol. 85: 517 – 533.en_US
dc.identifier.citedreferenceMarumo, F., M. Okubo, K. Yokota, H. Uchida, K. Kumano, T. Endo, K. Watanabe & N. Kashiwagi. 1988. A clinical study of renal transplant recipients receiving triple-drug therapy-cyclosporine A, mizoribine, and prednisolone. Transplant. Proc. 20: 406 – 409.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1749-6632.1993.tb35869.x.pdf
Size:
412.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.